ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Active Biotech Ab

Active Biotech Ab (0GQU)

2,85
0,00
( 0,00% )
Aktualisiert: 01:00:00

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
2,85
Gebot
0,00
Fragen
0,00
Volumen
0,00
0,00 Tagesbereich 0,00
2,85 52-Wochen-Bereich 2,85
Marktkapitalisierung
Handelsende
2,85
Handelsbeginn
-
Letzte Trade
(O)
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
48
Ausgegebene Aktien
361.739.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-22,51
Gewinn pro Aktie (EPS)
-0,13
Erlöse
-
Nettogewinn
-45,8M

Über Active Biotech Ab

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Diversified
Hauptsitz
Lund, Swe
Gegründet
1994
Active Biotech Ab is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0GQU. The last closing price for Active Biotech Ab was SEK2,85. Over the last year, Active Biotech Ab shares have traded in a share price range of SEK 2,85 to SEK 2,85.

Active Biotech Ab currently has 361.739.000 shares in issue. The market capitalisation of Active Biotech Ab is SEK1,03 billion. Active Biotech Ab has a price to earnings ratio (PE ratio) of -22.51.

0GQU Neueste Nachrichten

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage Lund, June 1, 2022...

Annual General Meeting of Active Biotech AB

Annual General Meeting of Active Biotech AB The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was...

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis   Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration...

Annual Report 2021 Active Biotech AB (publ)

Annual Report 2021 Active Biotech AB (publ) Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed...

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Active Biotech strengthens the patent protection for laquinimod in eye disorders Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office...

Active Biotech Interim Report Q1 2022

Active Biotech Interim Report Q1 2022 FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of...

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday...

Number of shares and votes in Active Biotech

Number of shares and votes in Active Biotech The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program...

Correction: Active Biotech Year End Report 2021

Correction: Active Biotech Year End Report 2021 The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The...

Active Biotech: Year End Report 2021

Active Biotech: Year End Report 2021 FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1002.852.852.8500DE
4002.852.852.851462.85DE
12002.852.852.85482.85DE
26002.852.852.85512.85DE
52002.852.852.85422.85DE
156002.852.852.853872.85DE
260002.852.852.856102.85DE
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
FARFerro-alloy Resources Limited
4,70p
(100,00%)
26,33M
VELAVela Technologies Plc
0,0075p
(36,36%)
191,01M
CASPCaspian Sunrise Plc
3,65p
(30,36%)
8,86M
ROCRockpool Acquisitions Plc
2,25p
(28,57%)
150k
RCGHRc365 Holding Plc
1,60p
(28,00%)
2,51M
NTOGNostra Terra Oil And Gas Company Plc
0,0235p
(-37,33%)
766,04M
SLFRSlf Realisation Fund Limited
1,02p
(-27,66%)
265,12k
QUIZQuiz Plc
4,02p
(-23,43%)
18,99k
PPSProton Motor Power Systems Plc
0,145p
(-19,44%)
5,44M
CNNCaledonian Trust Plc
45,00p
(-18,18%)
27,24k
NTOGNostra Terra Oil And Gas Company Plc
0,0235p
(-37,33%)
766,04M
NTVONativo Resources Plc
0,0023p
(0,00%)
517,61M
TRPTower Resources Plc
0,028p
(1,82%)
416,35M
HAYDHaydale Graphene Industries Plc
0,115p
(0,00%)
265,4M
UKOGUk Oil & Gas Plc
0,0245p
(-1,01%)
219,69M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht